Aradigm Company Profile (NASDAQ:ARDM)

About Aradigm (NASDAQ:ARDM)

Aradigm logoAradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company's lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies. Its partnered programs under development include Inhaled Ciprofloxacin. It is also engaged in developing Smoking Cessation Therapy (ARD-1600 Inhaled Nicotine). Its lead development candidates are its formulations of the potent antibiotic ciprofloxacin (Pulmaquin (ARD-3150) and Lipoquin (ARD-3100)) that are delivered by inhalation for the management of infections associated with the severe respiratory diseases, such as cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis (BE). Pulmaquin uses slow release liposomal formulation (Lipoquin) mixed with a small amount of ciprofloxacin dissolved in an aqueous medium.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ARDM
  • CUSIP: N/A
  • Web:
  • Market Cap: $19.39 million
  • Outstanding Shares: 14,800,000
Average Prices:
  • 50 Day Moving Avg: $1.25
  • 200 Day Moving Avg: $2.11
  • 52 Week Range: $0.78 - $7.19
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.45
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.88 million
  • Price / Sales: 10.31
  • Book Value: ($0.52) per share
  • Price / Book: -2.51
  • EBIDTA: ($24,570,000.00)
  • Net Margins: -32,717.14%
  • Return on Equity: -220.57%
  • Return on Assets: -105.09%
  • Debt-to-Equity Ratio: 1.53%
  • Current Ratio: 5.27%
  • Quick Ratio: 5.27%
  • Average Volume: 61,176 shs.
  • Beta: 1.14
  • Short Ratio: 1.44

Frequently Asked Questions for Aradigm (NASDAQ:ARDM)

What is Aradigm's stock symbol?

Aradigm trades on the NASDAQ under the ticker symbol "ARDM."

How were Aradigm's earnings last quarter?

Aradigm Co. (NASDAQ:ARDM) released its quarterly earnings results on Monday, May, 15th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.18. The firm had revenue of $1.69 million for the quarter. Aradigm had a negative return on equity of 220.57% and a negative net margin of 32,717.14%. View Aradigm's Earnings History.

Are investors shorting Aradigm?

Aradigm saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 57,291 shares, an increase of 25.8% from the April 13th total of 45,532 shares. Based on an average trading volume of 38,519 shares, the short-interest ratio is presently 1.5 days.

Who are some of Aradigm's key competitors?

Who owns Aradigm stock?

Aradigm's stock is owned by many different of retail and institutional investors. Top institutional investors include Grifols SA (48.30%), First Eagle Investment Management LLC (26.05%), Boxer Capital LLC (3.89%), Paulson & CO. Inc. (1.30%), FMR LLC (0.00%) and Vanguard Group Inc. (0.00%). View Institutional Ownership Trends for Aradigm.

Who sold Aradigm stock? Who is selling Aradigm stock?

Aradigm's stock was sold by a variety of institutional investors in the last quarter, including Boxer Capital LLC. View Insider Buying and Selling for Aradigm.

How do I buy Aradigm stock?

Shares of Aradigm can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Aradigm stock cost?

One share of Aradigm stock can currently be purchased for approximately $1.31.

Analyst Ratings

Consensus Ratings for Aradigm (NASDAQ:ARDM) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Aradigm (NASDAQ:ARDM)
No equities research coverage for this company has been tracked by


Earnings History for Aradigm (NASDAQ:ARDM)
Earnings by Quarter for Aradigm (NASDAQ:ARDM)
Earnings History by Quarter for Aradigm (NASDAQ:ARDM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2017Q1 2017($0.43)($0.25)$1.69 millionViewN/AView Earnings Details
3/28/2017Q4 2016($0.37)($0.54)$0.13 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.53)($0.55)$0.05 millionViewN/AView Earnings Details
8/10/2016Q2($0.59)($0.59)$0.01 millionViewN/AView Earnings Details
5/10/2016Q1($0.59)($0.55)$0.01 millionViewN/AView Earnings Details
3/15/2016Q415($0.55)($0.63)$0.04 millionViewN/AView Earnings Details
11/11/2015Q3($0.19)($0.38)$4.67 millionViewN/AView Earnings Details
8/13/2015Q2($0.08)($0.08)$11.60 million$10.00 millionViewN/AView Earnings Details
5/11/2015Q1($0.06)($0.08)$8.77 millionViewN/AView Earnings Details
3/17/2015Q414($0.07)($0.06)$6.70 million$8.10 millionViewN/AView Earnings Details
11/7/2014Q314($0.10)($0.06)$4.80 million$6.60 millionViewN/AView Earnings Details
8/7/2014Q214($0.09)($0.09)$4.25 million$12.20 millionViewN/AView Earnings Details
10/28/2013Q3 13($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Aradigm (NASDAQ:ARDM)
Current Year EPS Consensus Estimate: $-1.1000 EPS
Next Year EPS Consensus Estimate: $-0.3800 EPS


Dividend History for Aradigm (NASDAQ:ARDM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Aradigm (NASDAQ:ARDM)
Insider Ownership Percentage: 4.10%
Institutional Ownership Percentage: 43.59%
Insider Trades by Quarter for Aradigm (NASDAQ:ARDM)
Institutional Ownership by Quarter for Aradigm (NASDAQ:ARDM)
Insider Trades by Quarter for Aradigm (NASDAQ:ARDM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/4/2017Juergen Kurt FroehlichInsiderSell3,765$1.51$5,685.15View SEC Filing  
10/4/2016Juergen Kurt FroehlichInsiderSell423$6.76$2,859.48View SEC Filing  
6/21/2016Juergen Kurt FroehlichInsiderSell333$4.45$1,481.85View SEC Filing  
12/13/2013Virgil ThompsonDirectorSell3,340$0.17$567.80View SEC Filing  
8/27/2013First Eagle Investment ManagemMajor ShareholderBuy40,322,580$0.12$4,838,709.60View SEC Filing  
12/11/2012First Eagle Investment ManagemMajor ShareholderBuy41,666,667$0.12$5,000,000.04View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Aradigm (NASDAQ:ARDM)
Latest Headlines for Aradigm (NASDAQ:ARDM)
DateHeadline logoAradigm Co. (ARDM) Downgraded to Sell at Zacks Investment Research - May 23 at 4:24 PM logoAradigm Co. (ARDM) Issues Quarterly Earnings Results - May 16 at 3:24 PM logoAradigm Announces First Quarter 2017 Financial Results - May 15 at 4:04 PM logoAradigm reports 1Q loss - May 15 at 4:04 PM logoShort Interest in Aradigm Co. (ARDM) Expands By 25.8% - May 15 at 8:48 AM logoAradigm Co. (ARDM) Set to Announce Quarterly Earnings on Monday - May 5 at 11:12 PM logoAradigm Co. (ARDM) Scheduled to Post Quarterly Earnings on Monday - May 5 at 10:46 PM logoAradigm Co. (ARDM) Set to Announce Earnings on Monday - May 5 at 10:23 PM logoSomewhat Favorable Press Coverage Very Likely to Impact Aradigm (ARDM) Share Price - April 27 at 2:44 PM logoARADIGM CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - March 30 at 9:04 PM logoAradigm Announces Fourth Quarter 2016 and Full Year Financial Results - March 28 at 3:37 PM logoAradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2017 on February 13 - February 9 at 3:40 PM logoAradigm to Present at 9th Annual Biotech Showcase Conference on January 9 - January 6 at 3:43 PM logoARADIGM CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits - December 6 at 12:40 PM logoAradigm's Inhaled Antibiotic Fails Study (ARDM) - December 3 at 8:44 AM logoAradigm Lung Infection Antibiotic Fails Trial (ARDM) - December 2 at 9:01 PM logoAradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections ... - December 1 at 3:41 PM logoMid-Day Market Update: Crude Oil Up Over 4%; Express Shares Fall On Weak Outlook - December 1 at 3:41 PM logoAradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment … - December 1 at 3:41 PM logo7:03 am Aradigm announces top-line results from its two Phase 3 clinical trials evaluating the safety and efficacy of Pulmaquin (shares halted) - December 1 at 3:41 PM logoAradigm posts mixed late-stage data on inhaled antibiotic - December 1 at 3:41 PM logoAradigm Corp. drops 54% in pre-market trade on results of two late-stage clinical trials - December 1 at 3:41 PM logoAradigm Shares Plunge After Releasing Mixed Clinical Trial Results For Pulmaquin - December 1 at 3:41 PM logoWhat's In The Offing For These Biotech Stocks? - November 22 at 12:39 PM logoARADIGM CORP Financials - November 18 at 3:35 PM logoAradigm to Present at the Stifel 2016 Healthcare Conference on November 16 - November 10 at 2:05 PM logoMulti-million Dollar DTRA Funding for Biodefense Research with Aradigm’s Inhaled Ciprofloxacin - October 18 at 8:23 AM logoARDM Awaits Data In Q4, FDA Clears TCMD Device, Newfound Interest For GLMD, GALT - September 23 at 8:24 AM logo3 Reasons Why Aradigm Corporation (ARDM) is a Great Momentum Stock - September 22 at 3:31 PM logoAradigm (ARDM) Shares March Higher, Can It Continue? - September 22 at 9:26 AM logoAradigm to Present at the Ladenburg Thalmann 2016 Healthcare Conference on September 27 - September 20 at 9:29 AM logoARADIGM CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - June 10 at 5:02 PM logoTwo Presentations on Aradigm’s Inhaled Liposomal Ciprofloxacin Programs at the American Thoracic Society 2016 International Conference - May 11 at 7:00 AM



Aradigm (ARDM) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by Staff